Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $17.57.

Several equities analysts have recently weighed in on FOLD shares. Morgan Stanley lowered their price target on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. UBS Group lowered their price target on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Guggenheim raised Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Tuesday, May 14th. JPMorgan Chase & Co. decreased their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, March 18th. Finally, Bank of America decreased their target price on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, May 10th.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $9.92 on Friday. The business’s fifty day moving average price is $9.98 and its 200-day moving average price is $11.70. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -20.24 and a beta of 0.74. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.04. The firm had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $111.19 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The company’s revenue was up 27.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.18) EPS. On average, equities analysts predict that Amicus Therapeutics will post -0.12 earnings per share for the current year.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors have recently bought and sold shares of the business. Norges Bank purchased a new stake in Amicus Therapeutics in the 4th quarter worth $35,915,000. UBS Group AG grew its position in shares of Amicus Therapeutics by 58.1% during the fourth quarter. UBS Group AG now owns 824,708 shares of the biopharmaceutical company’s stock valued at $11,703,000 after purchasing an additional 303,038 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Amicus Therapeutics by 32.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,415,090 shares of the biopharmaceutical company’s stock valued at $34,270,000 after purchasing an additional 593,131 shares in the last quarter. Blackstone Inc. purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $35,008,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $1,178,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.